ISIS

Isis Pharmaceuticals, Inc. Press Releases

$42.28
*  
0.40
0.96%
Get ISIS Alerts
*Delayed - data as of Sep. 19, 2014  -  Find a broker to begin trading ISIS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin
9/17/2014 7:26:00 AM - PR Newswire

Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
9/3/2014 7:00:00 AM - PR Newswire

ATL1103 Phase II Trial - Successful Efficacy Results
9/2/2014 7:19:00 PM - PR Newswire

Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014
9/2/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
8/28/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
8/15/2014 7:00:00 AM - PR Newswire

Isis Reports Financial Results and Highlights for Second Quarter 2014
8/4/2014 8:30:00 AM - PR Newswire

Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
8/1/2014 7:00:00 AM - PR Newswire

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
7/28/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
7/17/2014 7:00:00 AM - PR Newswire

Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
7/16/2014 7:00:00 AM - PR Newswire

Biotech Equities Technical Momentum -- Research on Organovo, Prana Biotechnology, Isis Pharma, and Pharmacyclics
7/14/2014 7:04:00 AM - PR Newswire

Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program
7/2/2014 7:00:00 AM - PR Newswire